Berger E A, Moss B, Pastan I
Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Proc Natl Acad Sci U S A. 1998 Sep 29;95(20):11511-3. doi: 10.1073/pnas.95.20.11511.
The success of highly active anti-retroviral therapy (HAART) has inspired new concepts for eliminating HIV from infected individuals. A major obstacle is the persistence of long-lived reservoirs of latently infected cells that might become activated at some time after cessation of therapy. We propose that, in the context of treatment strategies to deliberately activate and eliminate these reservoirs, hybrid toxins targeted to kill HIV-infected cells be reconsidered in combination with HAART. Such combinations might also prove valuable in protocols aimed at preventing mother-to-child transmission and establishment of infection immediately after exposure to HIV. We suggest experimental approaches in vitro and in animal models to test various issues related to safety and efficacy of this concept.
高效抗逆转录病毒疗法（HAART）的成功激发了从感染个体中消除艾滋病毒的新观念。一个主要障碍是长期存在的潜伏感染细胞库，这些细胞在治疗停止后的某个时候可能会被激活。我们建议，在旨在故意激活并消除这些细胞库的治疗策略背景下，重新考虑将靶向杀死艾滋病毒感染细胞的杂合毒素与HAART联合使用。这种联合在旨在预防母婴传播以及在接触艾滋病毒后立即建立感染的方案中可能也被证明是有价值的。我们提出了体外和动物模型中的实验方法，以测试与这一观念的安全性和有效性相关的各种问题。
